US Bancorp
NRIX icon

US Bancorp’s Nurix Therapeutics NRIX Stock Holding History

US Bancorp’s Portfolio NRIX Stock Details NRIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$10K Buy
413
+164
+66% +$2.79K ﹤0.01% 3444
2026
Q1 		$3.86K Buy
249
+47
+23% +$779 ﹤0.01% 3642
2025
Q4 		$3.83K Sell
202
-28
-12% -$402 ﹤0.01% 3623
2025
Q3 		$2.13K Hold
230
– – ﹤0.01% 3750
2025
Q2 		$2.62K Sell
230
-12
-5% -$130 ﹤0.01% 3813
2025
Q1 		$2.88K Sell
242
-1,182
-83% -$19.8K ﹤0.01% 3797
2024
Q4 		$26.8K Buy
1,424
+842
+145% +$19.3K ﹤0.01% 3033
2024
Q3 		$13.1K Sell
582
-650
-53% -$14.7K ﹤0.01% 3267
2024
Q2 		$25.7K Buy
1,232
+928
+305% +$14.5K ﹤0.01% 2960
2024
Q1 		$4.47K Buy
304
+230
+311% +$2.47K ﹤0.01% 3554
2023
Q4 		$764 Sell
74
-113
-60% -$774 ﹤0.01% 3822
2023
Q3 		$1.47K Sell
187
-640
-77% -$5.84K ﹤0.01% 3709
2023
Q2 		$8.26K Buy
827
+8
+1% +$82 ﹤0.01% 3330
2023
Q1 		$7.27K Buy
819
+716
+695% +$7.46K ﹤0.01% 3399
2022
Q4 		$1.13K Sell
103
-166
-62% -$2K ﹤0.01% 3902
2022
Q3 		$4K Buy
269
+195
+264% +$3.09K ﹤0.01% 3677
2022
Q2 		$1K Hold
74
– – ﹤0.01% 3981
2022
Q1 		$1K Sell
74
-52
-41% -$923 ﹤0.01% 3965
2021
Q4 		$4K Buy
126
+74
+142% +$2.24K ﹤0.01% 3731
2021
Q3 		$2K Sell
52
-109
-68% -$3.36K ﹤0.01% 3901
2021
Q2 		$4K Buy
161
+153
+1,913% +$4.49K ﹤0.01% 3669
2021
Q1 		$0 Buy
+8
New +$303 ﹤0.01% 3940

Other funds holding NRIX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

US Bancorp's NRIX Position: Q2 2026 in Review

US Bancorp increased its Nurix Therapeutics (NRIX) stake by 66% in Q2 2026, buying an estimated $2.79K and bringing the position to 413 shares worth $10K. The position accounts for ﹤0.01% of the portfolio, ranked #3444.

US Bancorp first reported a position in NRIX in Q1 2021 and has held it in 22 quarters since. The position peaked at $26.8K in Q4 2024. 211 funds tracked by Wall St. Rank hold NRIX as of Q2 2026.

  • US Bancorp held 413 shares of Nurix Therapeutics worth $10K as of Q2 2026.
  • US Bancorp bought 164 Nurix Therapeutics shares in Q2 2026, an estimated $2.79K.
  • Nurix Therapeutics made up ﹤0.01% of US Bancorp's portfolio in Q2 2026, its #3444 holding.
  • US Bancorp first reported a position in Nurix Therapeutics in Q1 2021 and has held it in 22 quarters since.
  • US Bancorp's Nurix Therapeutics position peaked at $26.8K in Q4 2024.
  • 211 funds tracked by Wall St. Rank held Nurix Therapeutics as of Q2 2026.

Based on US Bancorp's 13F filing for Q2 2026, filed 12 Aug 2026.